DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / R•• T••• M••••••••• L••
R•• T••• M••••••••• L••
Red T••• Venture Capital is an early stage-biased life science venture firm that employs a targeted strategy of leveraging its deep relationships with leading West Coast academic and research institutions to source innovation emerging from those organizations.
venture manager, reported GAV $284M across 4 vehicles
Importance
26
moderate
Active deployment
25
moderate
Emerging
0
low
Completeness
69
high
Freshness
99
high
Research priority
10
low
Identity and regulatory footprint
- Headquarters
- Redwood City, CAadviserinfo.sec.gov
- Office address
- 2055 WOODSIDE ROAD, SUITE 270, Redwood City, CA, 94061adviserinfo.sec.gov
- Business phone
- 650-492-7900adviserinfo.sec.gov
- Website
- r•••••••••.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 16, 2026
- Private funds reported
- 5 (5 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $399Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business phone
- 650-492-7900adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
no observed deals yet
Stated (the firm’s website)
- Sectors
- biotech
- Stages
- seed, series a, series b, early
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors: no observed deals yet
lead rate n/afollow-on rate n/anew logos, 12 months 0
Funds and vehicles
4 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| R•• T••• S•• M•• L••• | SPV or co-invest vehicle | 2023 form d first sale | Active deployment | $5.1M Mar 29, 2024 | 1 | $5.0M of $5.0M | Nov 17, 2023 |
| R•• T••• V•••••• F•••• L••• | Fund | 2020 form d first sale | Mature | $274M Mar 29, 2024 | 164 | $177M of $250M | Dec 28, 2021 |
| R•• T••• V•••••• F••• S•• I• L•• | SPV or co-invest vehicle | 2020 form d first sale | Mature | $2.5M Mar 29, 2024 | 75 | $2.5M of $2.5M | Dec 14, 2020 |
| R•• T••• V•••••• F••• S•• I•• L•• | SPV or co-invest vehicle | unknown | Unknown | $2.0M Mar 29, 2024 | 75 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
20 current, 0 departed
J••••••• C••••••
Founder or executivePosition: Co-Founder and Chief Scientific Advisor
C••••• L••
Investor relationsPosition: VP of Investor Relations
H•••• L••••••
Managing partnerPosition: Co-Founder and Managing Partner
D•••••• N•••••
Operating partnerOperating Partner
R•• T••• V•••••• L•••
Operating partnerOperating Partner
B••• R•••••••
OtherPosition: Chief, Stanford Division of Immunology and Rheumatology
M••• D•
OtherM••• D•, Ph.D., is an immunology and biologics research and...
S•••• D•••
OtherPosition: Executive Committee, Wu Tsai Neuroscience Institute, Stanford
C••••• M••• L••••••
PartnerMember · since Dec 1, 2021
G••• Y••
PartnerPosition: Founding Member, UCSD Institute for Genomic Medicine
H•••• S•••• L••••••
PartnerManaging Director · since Feb 1, 2020
J••••• C•••••••
PartnerPosition: Managing Director
A••••• O•••••
Platform and operationsPosition: Executive Assistant
M•••••• P•••••
Platform and operationsPosition: Chief Financial Officer
M•••••• T••••• P•••••
Platform and operationsCfo · since Aug 1, 2020
Y••• S•••••••
Platform and operationsPosition: Executive Assistant
C•••••• M••••••
PrincipalPosition: Director, Stanford Center for Cancer Cell Therapy
K••• N•••••
PrincipalPosition: Former Director, Parker Center for Allergy & Asthma Research, Stanford
M••• M• D••••
PrincipalPosition: Director, Stanford Center for Human Systems Immunology
A••• S••••••••
Vice presidentVP of Biotherapeutics
Investments on record
0 edges, 0 companies, 0 partner-attributed
No investment on record yet. Edges arrive from the firm’s portfolio page, financing announcements, and Form D board seats.
Co-investors
0 relationships from shared deals, counted for the whole firm
No co-investor relationship yet: these are derived only from rounds and portfolio listings the graph has seen both investors on.
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
5 dated events
- Mar 29, 2024R•• T••• M••••••••• L•• first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2024R•• T••• S•• M•• L••• first reported on Form ADV by R•• T••• M••••••••• L•• (Venture Capital Fund), GAV $5,142,657Fund first reported on Form ADVFundsFactR•• T••• S•• M•• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2024R•• T••• V•••••• F••• S•• I• L•• first reported on Form ADV by R•• T••• M••••••••• L•• (Venture Capital Fund), GAV $2,500,000Fund first reported on Form ADVFundsFactR•• T••• V•••••• F••• S•• I• L••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2024R•• T••• V•••••• F•••• L••• first reported on Form ADV by R•• T••• M••••••••• L•• (Venture Capital Fund), GAV $258,655,680Fund first reported on Form ADVFundsFactR•• T••• V•••••• F•••• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2024R•• T••• V•••••• F••• S•• I•• L•• first reported on Form ADV by R•• T••• M••••••••• L•• (Venture Capital Fund), GAV $2,002,744Fund first reported on Form ADVFundsFactR•• T••• V•••••• F••• S•• I•• L••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $284M across 4 vehicles
Evidence
39 observations from 3 sources